Usefulness of procalcitonin at admission as a risk-stratifying biomarker for 50-day in-hospital mortality among patients with community-acquired bloodstream infection: an observational cohort study.

Date publication

janvier 2023

Journal

Biomarker research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GUEANT Jean-Louis , Pr THILLY Nathalie , Dr OUSSALAH Abderrahim

Tous les auteurs :
Oussalah A, Callet J, Manteaux AE, Thilly N, Jay N, Guéant JL, Lozniewski A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36647149

Résumé

To assess the association between plasma procalcitonin concentration at hospital admission and the risk of 50-day in-hospital mortality among patients with community-acquired bloodstream infections.

Mots clés

50-day in-hospital mortality, Community-acquired bloodstream infections, Procalcitonin, Risk-stratifying biomarker

Référence

Biomark Res. 2023 01 17;11(1):4